vimarsana.com

Page 3 - நுழைவு க்கு மருந்து அடித்தளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Why Covid-19 has provided pharma companies with the chance to show their value

SHARE The Covid-19 pandemic provided the pharmaceutical industry with an opportunity to showcase its social value proposition to the world. Not only has society been able to view the direct link between investments in research and development and the production of life-saving drugs, but the world has also witnessed unprecedented global collaboration between the public and private sector to bring these vaccines to market in record time. With the rise of environmental, social and governance investing and increased demand for companies to align their business practices to the United Nations’ Sustainable Development Goals, the pharmaceutical sector sits in a promising position to improve access to medicine in low- and middle-income countries.

More research funding needed to avoid drug-resistant pandemic, warns report

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making common infectious diseases such as pneumonia, tuberculosis and gonorrhoea harder to treat. Jayasree Iyer, executive director of the Access to Medicine Foundation, said: “Small and medium-sized companies are very critical for antimicrobial research. Big pharma has been leaving this space – only a small handful of companies are still developing drugs.” Big pharma is also involved in the $1bn AMR Action Fund, a collaboration with the WHO, European Investment Bank and Wellcome Trust, which was launched last July to support clinical-stage antibiotic research and aims to bring two to four new antibiotics to market by 2030.

Pneumococcal Vaccines Market: Asia Pacific Market to Grow at a Rapid Pace

Published: May 12, 2021 Transparency Market Research (TMR) has published a new report titled, “ Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise in health care expenditure, and surge in product approvals are projected to augment the global market from 2018 to 2026. Request Brochure of Report - Increase in Government Participation in Design & Implementation of Comprehensive Vaccination Programs to Propel Market

AstraZeneca Highlights Access To Healthcare As A Critical Pillar For Building Resilient Health Systems

AstraZeneca Highlights Access To Healthcare As A Critical Pillar For Building Resilient Health Systems
peacefmonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from peacefmonline.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.